Bracco Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BRACCO
BRACCO has forty-three approved drugs.
There are three US patents protecting BRACCO drugs.
Summary for Bracco
| US Patents: | 3 |
| Tradenames: | 66 |
| Ingredients: | 33 |
| NDAs: | 43 |
Drugs and US Patents for Bracco
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bracco | IOMERVU | iomeprol | SOLUTION;INTRAVENOUS | 216017-004 | Nov 27, 2024 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Bracco | HIPPUTOPE | iodohippurate sodium i-131 | INJECTABLE;INJECTION | 015419-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Bracco | ISOVUE-250 | iopamidol | INJECTABLE;INJECTION | 020327-002 | Oct 12, 1994 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Bracco
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bracco | CARDIOTEC | technetium tc-99m teboroxime kit | INJECTABLE;INJECTION | 019928-001 | Dec 19, 1990 | 6,056,941 | ⤷ Start Trial |
| Bracco | MULTIHANCE | gadobenate dimeglumine | INJECTABLE;INTRAVENOUS | 021357-003 | Nov 23, 2004 | 4,916,246 | ⤷ Start Trial |
| Bracco | MULTIHANCE | gadobenate dimeglumine | INJECTABLE;INTRAVENOUS | 021357-002 | Nov 23, 2004 | 4,916,246 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Bracco Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20220008827 | ⤷ Start Trial |
| Brazil | 112021022185 | ⤷ Start Trial |
| Japan | 2022527227 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bracco Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1874117 | 2014/032 | Ireland | ⤷ Start Trial | PRODUCT NAME: DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING DOLUTEGRAVIR SODIUM; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140121 |
| 1948158 | 1690020-1 | Sweden | ⤷ Start Trial | PRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123 |
| 2465580 | SPC/GB21/030 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: CABOTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING CABOTEGRAVIR SODIUM.; REGISTERED: UK EU/1/20/1481 (NI) 20201221; UK PLGB 35728/0055-57 20201221 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
